Plaintiff lawyers were optimistic Wednesday as a deadline loomed for approval of a $100 million national settlement of lawsuits against Merck & Co. over NuvaRing, a contraceptive linked to risk of blood clots.

Merck offered the settlement in February to settle on the condition that 95 percent of claimants, estimated at 3,800 nationwide, opt in.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]